PALB2 HEREDITARY BREAST CANCER

PALB2 Hereditary Breast Cancer — a high-penetrance breast cancer gene only recently reclassified, meaning thousands of patients received BRCA-negative results before PALB2 was added to standard panels.

Whole genome sequencing reads PALB2, BRCA1, BRCA2, and all ACMG-recommended hereditary cancer genes simultaneously — including patients who tested BRCA-negative years before PALB2 was recognized as a high-penetrance gene.

PALB2

About this condition

PALB2 Hereditary Breast Cancer Risk

PALB2 (partner and localizer of BRCA2) encodes a protein that functions as a molecular bridge linking BRCA1 to BRCA2 in the DNA damage response and homologous recombination pathway. Biallelic PALB2 pathogenic variants cause Fanconi anemia complementation group N — a severe bone marrow failure and cancer predisposition syndrome. Monoallelic (heterozygous) PALB2 pathogenic variants confer substantially elevated breast cancer risk. A landmark collaborative study published in the New England Journal of Medicine (2014) and confirmed by subsequent meta-analyses established an average cumulative lifetime breast cancer risk of approximately 35% for PALB2 pathogenic variant carriers overall, rising to 58% in carriers with a family history of breast cancer — effectively equivalent to BRCA2 in terms of penetrance.

PALB2 was formally reclassified as a high-penetrance breast cancer gene in 2014. This reclassification has direct clinical implications for all BRCA-negative patients who were tested under the prior paradigm when PALB2 was categorized as moderate-penetrance: patients who underwent hereditary breast cancer testing before 2015 may have an entirely negative-reported result that predates PALB2 high-penetrance recognition. PALB2 pathogenic variants also elevate ovarian cancer risk (estimated lifetime risk approximately 5-8%, lower than BRCA1/2) and pancreatic cancer risk. Male PALB2 carriers have elevated breast cancer risk.

Clinical management of PALB2 pathogenic variant carriers is evolving. Current NCCN guidelines (2024) recommend annual breast MRI with contrast beginning at age 30 for PALB2 carriers, with consideration of risk-reducing mastectomy based on family history and estimated lifetime risk. Carriers with a strong family history of breast cancer and lifetime risk approaching BRCA2-equivalent levels may be offered risk-reducing surgery under shared decision-making. PALB2 carriers with breast cancer may derive benefit from PARP inhibitor therapy — the therapeutic hypothesis underpinning several ongoing clinical trials, given PALB2's function in the BRCA1/2 homologous recombination pathway.

Gene locus: PALB2 (16p12.2)

Patients who tested BRCA-negative before 2015 may never have been tested for PALB2. Standard BRCA-focused panels that added PALB2 later often use limited sequencing approaches that miss structural variants.

A BRCA-negative result is not the same as a negative hereditary breast cancer result

The commercial hereditary cancer testing market was built around BRCA1 and BRCA2. For many years, 'BRCA testing' was the de facto hereditary breast cancer test. PALB2's reclassification as high-penetrance in 2014 created a gap: patients who received BRCA-only results before that date have a formally incomplete hereditary cancer assessment. Additionally, some multi-gene panels added PALB2 after the fact with limited sequencing coverage that does not detect large deletions or deep intronic variants. Whole genome sequencing provides complete PALB2 sequencing as part of a comprehensive hereditary cancer assessment — including all BRCA1/2, PALB2, CHEK2, ATM, and ACMG-recommended cancer genes simultaneously.

PALB2 status informs PARP inhibitor eligibility — a directly actionable clinical decision

Olaparib and talazoparib — PARP inhibitors approved for BRCA1/2-mutated breast cancer — exploit homologous recombination deficiency caused by loss of BRCA1/2 function. PALB2 functions in the same HR pathway, and emerging clinical trial data suggest PALB2 carriers with breast cancer may respond to PARP inhibitor treatment. Ongoing trials including OlympiAD extension cohorts and the PATINA trial are evaluating PARP inhibitors specifically in PALB2-positive patients. Knowing PALB2 status at the time of a breast cancer diagnosis may determine clinical trial eligibility and inform treatment selection — a decision that requires a complete hereditary cancer gene panel result, not a historical BRCA-only test.

PALB2 Hereditary Breast Cancer — a high-penetrance breast cancer gene only recently reclassified, meaning thousands of patients received BRCA-negative results before PALB2 was added to standard panels.

PALB2 Hereditary Breast Cancer Risk

Patients who tested BRCA-negative before 2015 may never have been tested for PALB2. Standard BRCA-focused panels that added PALB2 later often use limited sequencing approaches that miss structural variants.

A BRCA-negative result is not the same as a negative hereditary breast cancer result

PALB2 status informs PARP inhibitor eligibility — a directly actionable clinical decision

Others in Hereditary Cancer

One test. A lifetime of answers.